LDL-C≥190 mg/dL男性一级预防中降脂治疗的获益:WOSCOPS 5年随机试验与20年观察随访分析
该研究对WOSCOPS试验中无血管疾病的5529名男性进行事后分析,按LDL-C水平分层。在LDL-C≥190 mg/dL亚组中,普伐他汀使冠心病风险降低27%、主要不良心血管事件降低25%,20年随访中冠心病死亡、心血管死亡和全因死亡分别降低28%、25%和18%。
要点
- LDL-C≥190 mg/dL无血管疾病男性,普伐他汀降低冠心病和MACE风险。
- 该亚组20年随访中冠心病死亡、心血管死亡和全因死亡均显著降低。
- 降脂获益在LDL-C≥190与<190 mg/dL亚组间无显著交互作用。
核心结论
- 在LDL-C≥190 mg/dL且无血管疾病男性中,降低LDL-C对心血管疾病一级预防具有短期和长期获益。
研究设计与样本
- WOSCOPS随机安慰剂对照试验事后分析及试验后观察随访,排除基线有血管疾病证据者。
- 纳入5529名无血管疾病男性,按LDL-C分为<190 mg/dL组(n=2969,均值178±6 mg/dL)和≥190 mg/dL组(n=2560,均值206±12 mg/dL)。
- 随机阶段4.9年,比较普伐他汀40 mg/d与安慰剂对冠心病和MACE的影响,总随访20年评估死亡结局。
主要发现
- 5529名无血管疾病者中,普伐他汀使冠心病风险降低27%(P=0.002),MACE降低25%(P=0.004),LDL-C≥190与<190亚组间一致(交互P>0.9)。
- LDL-C≥190 mg/dL亚组中,试验阶段普伐他汀使冠心病风险降低27%(P=0.033),MACE降低25%(P=0.037)。
- LDL-C≥190 mg/dL亚组20年随访中,冠心病死亡降低28%(P=0.020),心血管死亡降低25%(P=0.009),全因死亡降低18%(P=0.004)。
临床怎么用
- 对LDL-C≥190 mg/dL且无血管疾病的男性,可启动他汀治疗以进行心血管疾病一级预防。
- 他汀治疗的获益在短期随机阶段和长期观察随访中均持续存在。
局限性
- 本研究为WOSCOPS试验的事后分析。
- 研究人群仅限45至64岁男性,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with primary elevations of low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL are at a higher risk of atherosclerotic cardiovascular disease as a result of long-term exposure to markedly elevated LDL-C levels. Therefore, initiation of statin therapy is recommended for these individuals. However, there is a lack of randomized trial evidence supporting these recommendations in primary prevention. In the present analysis, we provide hitherto unpublished data on the cardiovascular effects of LDL-C lowering among a primary prevention population with LDL-C ≥190 mg/dL. METHODS: We aimed to assess the benefits of LDL-C lowering on cardiovascular outcomes among individuals with primary elevations of LDL-C ≥190 mg/dL without preexisting vascular disease at baseline. We performed post hoc analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) randomized, placebo-controlled trial, and observational posttrial long-term follow-up, after excluding individuals with evidence of vascular disease at baseline. WOSCOPS enrolled 6595 men aged 45 to 64 years, who were randomly assigned to pravastatin 40 mg/d or placebo. In the present analyses, 5529 participants without evidence of vascular disease were included, stratified by LDL-C levels into those with LDL-C <190 mg/dL (n=2969; mean LDL-C 178±6 mg/dL) and those with LDL-C ≥190 mg/dL (n=2560; mean LDL-C 206±12 mg/dL). The effect of pravastatin versus placebo on coronary heart disease and major adverse cardiovascular events were assessed over the 4.9-year randomized controlled trial phase and on mortality outcomes over a total of 20 years of follow-up. RESULTS: Among 5529 individuals without vascular disease, pravastatin reduced the risk of coronary heart disease by 27% (P=0.002) and major adverse cardiovascular events by 25% (P=0.004) consistently among those with and without LDL-C ≥190 mg/dL (P-interaction >0.9). Among individuals with LDL-C ≥190 mg/dL, pravastatin reduced the risk of coronary heart disease by 27% (P=0.033) and major adverse cardiovascular events by 25% (P=0.037) during the initial trial phase and the risk of coronary heart disease death, cardiovascular death, and all-cause mortality by 28% (P=0.020), 25% (P=0.009), and 18% (P=0.004), respectively, over a total of 20 years of follow-up. CONCLUSIONS: The present analyses provide robust novel evidence for the short- and long-term benefits of lowering LDL-C for the primary prevention of cardiovascular disease among individuals with primary elevations of LDL-C ≥190 mg/dL.
引用
- Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. Circulation. 2017. PMID: 28877913. doi:10.1161/CIRCULATIONAHA.117.027966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。